Molecular classification guides for the postoperative adjuvant therapy of early-stage endometrial carcinoma

Abstract

Surgical treatment has been widely used for early-stage endometrial carcinoma patients, but 15-20% of patients had a poor prognosis, requiring a postoperative adjuvant therapy. With the development of molecular classification of endometrial carcinoma, the combination of molecular and clinicopathological factors can guide the prognosis risk assessment and make the adjuvant therapy selection more accurate, as a result, the survival outcome of patients can be greatly improved. In this article, the molecular classification of endometrial carcinoma is reviewed, and its guidance to the postoperative adjuvant therapy for early-stage endometrial carcinoma is discussed. It concludes that the molecular classification opens up the opportunity of creating new ideas for adjuvant treatment strategies for early endometrial cancer.